Catherine Arnst on Muck Rack

Catherine Arnst

Newburyport
As seen in: Quartz, Yahoo Life, Yahoo Singapore, Yahoo Finance, Boston.com, Flipboard, The Boston Globe, Yahoo, Currently
Covers:  biotech, pharmaceuticals, health
Writer/Communications strategist specializing in medicine/health care. Formerly @UnitedHospFund, @RWJF, @BW, @Reuters. Opinions expressed my own.

Get in touch with Catherine

Contact Catherine, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Catherine Arnst’s Biography

Read Full Bio →

Cover life sciences on the east coast for Xconomy.com. Previously spent 15 years as senior medical writer at BusinessWeek. Interested in biopharma research, health care delivery and health care policy.

Articles

Les grandes entreprises pharmaceutiques sont prêtes à récolter les fruits de leurs investissements dans les médicaments à base d'IA.

|
By Catherine Arnst
| Quartz
L'industrie pharmaceutique a massivement investi dans l'intelligence artificielle au cours des dernières années, mais elle n'a pas encore vu un retour sur investissement sous forme de médicament développé par IA prêt pour le marché. Cela pourrait bientôt changer. Le premier médicament découvert et conçu à l'aide de l'IA, Insilico Medicine’s Rentosertib, devrait entrer dans un essai clinique de Phase 3 dans les 18 prochains mois, la dernière étape avant de demander l'approbation de la FDA.
Open in Who Shared Issue with article?

Big Pharma is ready for its AI drug investments to pay off Original

|
By Catherine Arnst
| Quartz
The pharmaceutical industry has made massive investments in artificial intelligence over the past several years, but it's yet to see a payoff in terms of a market-ready, AI-developed drug. That could soon change. The first drug discovered and designed using AI, Insilico Medicine’s Rentosertib, is likely to enter a Phase 3 clinical trial in the next 18 months, the final stage before seeking FDA approval. And it will reach that milestone in record time.
Open in Who Shared View Duplicates (2) Issue with article?

Lilly affirme qu'une pilule contre l'obésité peut remplacer l'injection après une perte de poids.

|
By Catherine Arnst
| Quartz
Eli Lilly a rapporté jeudi que l'orforglipron, sa pilule expérimentale pour l'obésité, a aidé la majorité des patients dans un essai clinique à maintenir leur perte de poids après être passés de formes injectables de son médicament Zepbound GLP-1 et de Wegovy de Novo Nordisk.
Open in Who Shared Issue with article?
See all 119 licensed articles (120 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Catherine

Contact Catherine, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified